We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

37 hedge funds and large institutions have $92.7M invested in SAB Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

42% more funds holding

Funds holding: 26 → 37 (+11)

41% more capital invested

Capital invested by funds: $65.9M → $92.7M (+$26.9M)

1.82% more ownership

Funds ownership: 4.53% → 6.36% (+1.8%)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

Holders
37
Holders Change
+11
Holders Change %
+42.31%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
6
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$5.28M
2
KC
Kepos Capital
New York
+$5.24M
3
KIM
Karpus Investment Management
New York
+$4.38M
4
BFM
Boothbay Fund Management
New York
+$3.97M
5
CH
CVI Holdings
Delaware
+$3.47M

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$5.09M
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$979K
3
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$496K
4
MSU
Mizuho Securities USA
New York
-$205K
5
WAM
Wolverine Asset Management
Illinois
-$182K
Name Holding Trade Value Shares
Change 		Change in
Stake
KIM
1
Karpus Investment Management
New York
$10.3M +$4.38M +44,134 +74%
BCM
2
Basso Capital Management
Connecticut
$6.84M – – –
PC
3
Periscope Capital
Ontario, Canada
$5.98M – – –
SCM
4
Shaolin Capital Management
Florida
$5.32M +$132K +1,326 +3%
GCL
5
Glazer Capital LLC
New York
$5.3M +$5.28M +53,250 New
KC
6
Kepos Capital
New York
$5.26M +$5.24M +52,823 New
Hudson Bay Capital Management
7
Hudson Bay Capital Management
Connecticut
$4.99M – – –
PAMP
8
Polar Asset Management Partners
Ontario, Canada
$4.98M – – –
FTCM
9
Fir Tree Capital Management
New York
$4.49M -$1.39K -14 -0%
WRBC
10
W.R. Berkley Corp
Connecticut
$4.21M +$625K +6,298 +18%
ASM
11
ATW SPAC Management
New York
$3.98M +$3.97M +40,000 New
BFM
12
Boothbay Fund Management
New York
$3.98M +$3.97M +40,000 New
CH
13
CVI Holdings
Delaware
$3.49M +$3.47M +35,000 New
RCM
14
Radcliffe Capital Management
Pennsylvania
$3.49M – – –
HSBC Holdings
15
HSBC Holdings
United Kingdom
$2.74M -$979K -9,868 -26%
MSU
16
Mizuho Securities USA
New York
$2.65M -$205K -2,064 -7%
YCM
17
Yakira Capital Management
Connecticut
$2.5M +$2.49M +25,070 New
PMAM
18
Picton Mahoney Asset Management
Ontario, Canada
$2.49M -$496K -5,000 -17%
SCM
19
Saba Capital Management
New York
$1.5M – – –
WAM
20
Wolverine Asset Management
Illinois
$1.35M -$182K -1,833 -12%
AA
21
AQR Arbitrage
Connecticut
$1.13M +$673K +6,786 +151%
RCM
22
Rivernorth Capital Management
Florida
$996K – – –
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$830K +$825K +8,318 New
Goldman Sachs
24
Goldman Sachs
New York
$731K – – –
Walleye Trading
25
Walleye Trading
New York
$518K +$515K +5,195 New
1
2

SABS Hedge Fund Activity: Q2 2021 in Review

37 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2021, worth a combined $92.7M — up 41% from $65.9M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SABS positions and 4 closed out — a net gain of 11 holders — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $5.28M. The largest seller was Mangrove Partners, exiting entirely with an estimated $5.09M sold.

  • 37 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2021, up from 26 in Q1 2021.
  • Funds reported $92.7M of SAB Biotherapeutics stock for Q2 2021, up 41% quarter-over-quarter.
  • 15 funds opened new SAB Biotherapeutics positions in Q2 2021 and 4 closed out, a net change of +11 holders.
  • The largest SAB Biotherapeutics buyer in Q2 2021 was Glazer Capital LLC, an estimated $5.28M added.
  • The largest SAB Biotherapeutics seller in Q2 2021 was Mangrove Partners, an estimated $5.09M sold.

Based on aggregated 13F filings for Q2 2021.